Enhanced passive surveillance of influenza vaccination in England, 2016−2017– an observational study using an adverse events reporting card-Reference-Cited by-同舟云学术

Enhanced passive surveillance of influenza vaccination in England, 2016−2017– an observational study using an adverse events reporting card

Published:2019-03-20 Issue:5 Volume:15 Page:1048-1059
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

de Lusignan Simon¹^ORCID,Ferreira Filipa¹^ORCID,Damaso Silvia²^ORCID,Byford Rachel¹^ORCID,Pathirannehelage Sameera¹^ORCID,Yeakey Anne³^ORCID,Yonova Ivelina¹^ORCID,Schuind Anne⁴^ORCID,Dos Santos Gael⁵^ORCID

Affiliation:

1. Department of Clinical & Experimental Medicine, University of Surrey, Guildford, UK

2. Biostatistics EPI, GSK, Wavre, Belgium

3. Clinical Safety & Pharmacovigilance, GSK, Rockville, MD, USA

4. Clinical R&D, GSK, Rockville, MD, USA

5. Clinical R&D, GSK, Wavre, Belgium

Funder

GlaxoSmithKline Biologicals SA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2019.1565258

Reference27 articles.

1. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study

2. The “Fluad Case” in Italy: Could it have been dealt differently?

3. The Public Health Impact of the So-Called “Fluad Effect” on the 2014/2015 Influenza Vaccination Campaign in Italy: Ethical Implications for Health-Care Workers and Health Communication Practitioners

4. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden

5. Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced Safety Surveillance of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season;Drug Safety;2024-06-29

2. An 8-Year Prospective, Observational, Multi-centre Post-Marketing Safety Surveillance Study Conducted in South Korea (2014–2022) Following the Introduction of GSK’s Inactivated Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) for Subjects Aged 6 Months and Older;Drug Safety;2024-03-14

3. Real-World Evidence of Point-of-Care Glucometers: Enhanced Passive Surveillance and Adverse Event Reporting Status in Korea and the United States;Annals of Laboratory Medicine;2023-04-21

4. Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient‐reported outcome system for vaccine safety remote monitoring;Influenza and Other Respiratory Viruses;2023-03

5. Enhanced passive safety surveillance of Influvac® and Influvac® Tetra: Results from seven consecutive seasons;Vaccine;2023-01